Tag Archives: M&A

AbbVie will buy Shire in another Pharma tax inversion strategy

Posted on July 18, 2014 by Alexander Szewczak

Following on the heels of Mylan, AbbVie will buy Shire in a move that, among other things, will result in a significantly lower tax rate when the redomiciled company is fully headquartered in Ireland. More information can be found here (WSJ) and here … Continue reading →

Posted in Economics, Pharmaceutical Industry | Tagged , , , , | 1 Comment

Pharma megamergers — against the spirit of the times?

Posted on April 23, 2014 by Alexander Szewczak

Here’s more on the Novartis-GSK-Lilly three way deal announced Tuesday.  As WSJ journalist Helen Thomas writes, the megamerger chill of dread felt when rumors of Pfizer’s stalking of AZ came to light last weekend may well be exorcized by this … Continue reading →

Posted in Fixing Big Pharma Research, Pharmaceutical Industry | Tagged , , , , , , | 1 Comment

Pharma deal frenzy points to fundamental change in strategy

Posted on April 23, 2014 by Alexander Szewczak

Pharmaceutical giants Novartis and GSK announced a large swap in business units on Tuesday, resulting in both companies becoming significantly more specialized — reversing their decades-long traditional strategies of greater diversification across product lines. The Wall Street Journal has more than … Continue reading →

Posted in Pharmaceutical Industry | Tagged , , , , , | 1 Comment